A unique platform that resulted in a promising HIV vaccine has also led to a new, highly effective vaccine against tuberculosis that is moving toward testing in humans.
The new vaccine completely protected 41 percent and reduced overall TB disease by 68 percent in vaccinated rhesus macaques, according to a study published as an Advanced Online Publication of Nature Medicine. In contrast, there was no measurable protection in the rhesus macaques -- a monkey species that is closely related to humans -- treated with today's standard TB vaccine, the Bacillus Calmette-Guérin vaccine. [1]
Human clinical trial starts in 2020, according to the information from the inventors of the vaccine.
Oregon Health & Science University. "Fresh approach to TB vaccine offers better protection: New vaccine completely protected 41 percent of nonhuman primates, standard vaccine protected none." ScienceDaily. ScienceDaily, 17 January 2018
http://www.sciencedaily.com/releases/2018/01/180117114910.htm
05/04/2018
